EML4 and non-small cell lung carcinoma: In a pilot study, EML4-ALK translocation was detected in plasma-derived EVs of patients with NSCLC, suggesting that EVs may serve as an additional tool to guide treatment with ALK inhibitors (Reclusa et al., 2019).